This complimentary CME educational activity is designed for all cardiology-focused physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors managing, referring, and/or consulting on patients with atrial fibrillation, with a focus on stroke prevention. We welcome neurology-focused clinicians with a medical and educational needs in the fields of general cardiology, and other providers that are part of the multidisciplinary team caring for patients with these and related conditions, including:
Heart failure specialists
Coronary care unit (CCU) specialists and directors
Clinical pharmacists and pharmacologists
Pharmacy directors (cardiovascular medicine)
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period December 22, 2010 through December 22, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 94 segments to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form; and 4) print out CME certificate.
Estimated Time to Complete Educational Activity
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in stroke prevention in the setting of atrial fibrillation.
December 22, 2010
December 22, 2012
Participation in this iQ&A interactive Medical Intelligence Zone for Stroke Prevention in Atrial Fibrillation is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Supported by an educational grant from Ortho-McNeil Inc, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Samuel Z. Goldhaber, MD Program Chairman and Moderator
Professor of Medicine
Harvard Medical School
Director, VTE Research Group
Brigham and Women's Hospital
President, North American Thrombosis Forum (NATF)
Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis. Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis
Richard C. Becker, MD
Professor of Medicine
School of Medicine
Director, Duke Cardiovascular Thrombosis Center
Duke Clinical Research Institute
Durham, North Carolina USA
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital and the VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex. Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company
Michael D. Ezekowitz, MD, PhD
Professor and Vice President
Lankenau Institute for Medical Research
Main Line Hospitals
John Fanikos, RPh, MBA
Director of Pharmacy Business and Financial Services
Brigham and Women’s Hospital
Adjunct Clinical Professor of Pharmacy
Massachusetts College of Pharmacy
Valentin Fuster, MD, PhD
Director, Mount Sinai Heart
Director, Zena and Michael Wiener Cardiovascular Institute and the Marie-Josée and Henry R Kravis Center of Cardiovascular Health
Richard Gorlin MD Heart Research Foundation Professor of Cardiology at Mount Sinai Medical Center
New York, NY
Nothing to disclose
David A. Garcia, MD
Associate Professor, Division of General Internal Medicine
University of New Mexico
Co-Director, University of New Mexico Anticoagulation Management Service
President, Anticoagulation Forum
Albuquerque, New Mexico USA
Advisor or consultant for: Bohringer Ingelhim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, ARYx Therapeutics, CSL Behring. Received grants for clinical research from: Bristol-Myers Squibb Company, ARYx Therapeutics, CSL Behring
Christopher B. Granger, MD
Professor of Medicine
Cardiac Care Unit; Co-Director
Cardiovascular Clinical Trials
Duke University Medical Center
Durham, North Carolina
Advisor or Consultant: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; sanofi-aventis; The Medicines Company Grants/Research Support: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Medtronic, Inc.; Merck & Co., Inc.; sanofi-aventis; The Medicines Company
Jonathan L. Halperin, MD
Mount Sinai School of Medicine
Director, Clinical Cardiology Service
The Zena and Michael A. Wiener Cardiovascular Institute
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
New York, New York
Jeffrey I. Weitz, MD, FRCP, FACP
Professor of Medicine and Biochemistry
Director, Henderson Research Center
Canada Research Chair in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research
Salim Yusuf, MD
Professor of Medicine
Population Health Research Institute
Grants/Research Support: sanofi-aventis and Bristol-Myers Squibb Company Advisor or Consultant: sanofi-aventis and Bristol-Myers Squibb Company Speaker or Speakers Bureau: sanofi-aventis and Bristol-Myers Squibb Company
Program Managers and Web Editor Disclosure Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.
Upon completion of this activity, participants will:
Have a better, more scientific and clinically relevant understanding of advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade; and the possible implications of these advances for prophylaxis of arterial thromboembolism in the setting of atrial fibrillation
Be able to apply national guidelines—including those issues by the ACC, AHA, , ASA, ACCP, and others—so that they can overcome practice gaps and improve thrombosis management and clinical outcomes in patients with AF and other risk factors for stroke.
Have a better, more scientific and evidence-based understanding of how systemic anticoagulation can proven of stroke in the setting of AF, and be better skilled at using multiple approaches, including established, evidence-based, guideline-sanctioned treatments with VKAs and, when available, emerging therapies affecting other targets in the coagulation cascade.
Better understand the epidemiology, scope of problem, risk stratification (CHADS2), landmark trials, national guidelines, and the multidimensional therapeutic landscape of antithrombotic strategies shown to be useful for stroke risk reduction in AF.
Have a better, more scientific understanding of the mechanisms involved in thromboembolic prevention in heart disease and the rationale for identifying agents with predictable anticoagulation, in the absence of clinical monitoring.
Have a better, more scientific understanding about novel approaches for residual risk reduction and secondary prevention of adverse thromboembolic events (stroke) in the setting of atrial fibrillation and be able to make more evidence-based clinical decisions that account for both thrombosis mitigation and bleeding risks when selecting anticoagulation strategies.
Be able to apply the landmark clinical trials focusing on thromboembolic risk prevention in patients with atrial fibrillation to the front lines of clinical practice in order to reduce stroke risk.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.